Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 19/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | HTR1A | P08908 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
| ▸ | HRH1 | P35367 | 1/20 | 0.65 |
| ▸ | HTR2B | P41595 | 1/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.65 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7591196 | 0.99 | TACR1 (0.79) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL7584046 | 0.94 | TACR1 (0.82) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL7588537 | 0.93 | TACR1 (0.81) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL7591872 | 0.92 | TACR1 (0.82) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL6230989 | 0.92 | TACR1 (0.82) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL7587996 | 0.91 | TACR1 (0.81) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL7586350 | 0.90 | TACR1 (0.74) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL7584702 | 0.90 | TACR1 (0.68) | TACR1CYP2D6KCNH2 | |
| SCHEMBL6554836 | 0.89 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL7592042 | 0.89 | TACR1 (0.67) | TACR1CYP2D6KCNH2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6562335-B1 | NK-1 receptor antagonists for prevention of neurogenic inflammation in gene therapy | PFIZER, INC. | 2003-05-13 | — | — | US | claimed |
| EP-0780375-B1 | 3-((5-substituted benzyl)amino)-2-phenylpiperidines as substance p antagonists | PFIZER (US) | 2002-09-11 | — | — | EP | claimed |
| EP-0854720-B1 | NK-1 RECEPTOR ANTAGONISTS FOR PREVENTION OF NEUROGENIC INFLAMMATION IN GENE THERAPY | PFIZER (US) | 1999-08-04 | — | — | EP | claimed |
| EP-0854720-A1 | NK-1 RECEPTOR ANTAGONISTS FOR PREVENTION OF NEUROGENIC INFLAMMATION IN GENE THERAPY | PFIZER INC. (US) | 1998-07-29 | — | — | EP | claimed |
| EP-0780375-A1 | 3-((5-substituted benzyl)amino)-2-phenylpiperidines as substance p antagonists | PFIZER INC. (US) | 1997-06-25 | — | — | EP | claimed |
| EP-0773026-A2 | NK-1 receptor antagonists for the treatment of cancer | PFIZER INC. (US) | 1997-05-14 | — | — | EP | claimed |
| WO-1997013514-A1 | NK-1 RECEPTOR ANTAGONISTS FOR PREVENTION OF NEUROGENIC INFLAMMATION IN GENE THERAPY | PFIZER INC. (US) | 1997-04-17 | — | — | WO | claimed |
| US-6562335-B1 | NK-1 receptor antagonists for prevention of neurogenic inflammation in gene therapy | PFIZER, INC. | 2003-05-13 | — | — | US | disclosed |
| EP-0780375-B1 | 3-((5-substituted benzyl)amino)-2-phenylpiperidines as substance p antagonists | PFIZER (US) | 2002-09-11 | — | — | EP | disclosed |
| US-6194436-B1 | THERAPY FOR LUNG CANCER | PFIZER INC. | 2001-02-27 | — | — | US | disclosed |
| US-5990125-A | NK-1 receptor antagonists for the treatment of cancer | PFIZER INC. (US) | 1999-11-23 | — | — | US | disclosed |
| EP-0854720-B1 | NK-1 RECEPTOR ANTAGONISTS FOR PREVENTION OF NEUROGENIC INFLAMMATION IN GENE THERAPY | PFIZER (US) | 1999-08-04 | — | — | EP | disclosed |
| US-5789423-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS; GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC. (US) | 1998-08-04 | — | — | US | disclosed |
| EP-0854720-A1 | NK-1 RECEPTOR ANTAGONISTS FOR PREVENTION OF NEUROGENIC INFLAMMATION IN GENE THERAPY | PFIZER INC. (US) | 1998-07-29 | — | — | EP | disclosed |
| EP-0780375-A1 | 3-((5-substituted benzyl)amino)-2-phenylpiperidines as substance p antagonists | PFIZER INC. (US) | 1997-06-25 | — | — | EP | disclosed |
| EP-0773026-A2 | NK-1 receptor antagonists for the treatment of cancer | PFIZER INC. (US) | 1997-05-14 | — | — | EP | disclosed |
| WO-1997013514-A1 | NK-1 RECEPTOR ANTAGONISTS FOR PREVENTION OF NEUROGENIC INFLAMMATION IN GENE THERAPY | PFIZER INC. (US) | 1997-04-17 | — | — | WO | disclosed |